trending Market Intelligence /marketintelligence/en/news-insights/trending/UjUIX4Z2vvKoFk4ElwUIoQ2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

AVEO, Biodesix report results from phase 1 trials of cancer drug

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


AVEO, Biodesix report results from phase 1 trials of cancer drug

AVEO Pharmaceuticals Inc. and its partner Biodesix Inc. reported results from a phase 1 trial combining their drug candidate ficlatuzumab with cetuximab to treat cetuximab-resistant metastatic head and neck squamous cell carcinoma.

Cetuximab is a chemotherapy treatment.

The study data, presented at the American Society of Clinical Oncology, showed a disease control rate of 67% and prolonged progression-free and overall survival compared to historical controls.

The drug combination was well tolerated and achieved an overall response rate of 17% along with a median progression-free survival of six months and overall survival of 8.2 months.

The company expects to initiate a phase 2 trial for the combination therapy in the second half.

AVEO and Biodesix also announced results from a phase 1 study combining ficlatuzumab with chemotherapy drug cytarabine to treat high-risk relapsed or refractory acute myeloid leukemia.

The study, which enrolled nine patients, demonstrated early signs of tolerability and activity with a 50% complete response rate.

The company, however, also reported one death in the trial, due to sepsis and multi-organ failure.